..

Journal des maladies et troubles inflammatoires de l'intestin

Soumettre le manuscrit arrow_forward arrow_forward ..

Volume 8, Problème 3 (2023)

Mini-revue

Exploring Pathways in Inflammatory Bowel Disorders: The Latest Research in IBD

Christopher Ralston

Inflammatory Bowel Disorders (IBD) comprise a group of chronic gastrointestinal conditions characterized by inflammation of the digestive tract. This article delves into the latest research in IBD, encompassing its complex pathogenesis, novel therapeutic avenues, and potential breakthroughs. By examining the intricate pathways involved in disease development and progression, this review aims to contribute to a deeper understanding of IBD and its management.
Mini-revue

Breaking Down Autoimmunity: Understanding the Body′s Defense Turned Against Itself

Jenio Yuan

Autoimmunity, a complex phenomenon, occurs when the immune system mistakenly targets the body's own cells and tissues. This article delves into the mechanisms behind autoimmunity, factors contributing to its development, common autoimmune disorders, and management strategies. The immune system's intricate dance of self-recognition and the breakdown of self-tolerance are explored. Genetics and environmental triggers play a crucial role in predisposing individuals to autoimmune disorders. Highlighting well-known conditions like rheumatoid arthritis, systemic lupus erythematous, type 1 diabetes, multiple sclerosis, and Hashimoto's thyroiditis, this article provides insight into the diversity of autoimmune disorders. Management approaches, including immunosuppressive medications, anti-inflammatory treatments, biological therapies, and lifestyle modifications, are discussed. The article concludes by highlighting advancements in research that offer hope for improved understanding and treatment of autoimmune disorders, emphasizing a future where affected individuals experience enhanced quality of life.
Mini-revue

Surgical Interventions in Inflammatory Bowel Diseases: Navigating Bowel Resections and Beyond

Martin Marcel

Inflammatory Bowel Diseases (IBD) encompass a group of chronic inflammatory conditions affecting the gastrointestinal tract, with Crohn's disease and ulcerative colitis as prominent examples. While medical management remains the cornerstone of IBD treatment, a subset of patients requires surgical intervention to alleviate symptoms, manage complications, and enhance their quality of life. Bowel surgery in the context of IBD has evolved significantly, offering various techniques and advancements aimed at optimizing outcomes. This abstract provides a concise overview of the indications, techniques, outcomes, and recent advancements in bowel surgery for IBD.
Article de révision

Current Therapeutic Approaches in Acid Peptic Disease

P. Vinod Kumar*, Prince Louis Palatty and Achuthan CR

Around 8 million people die every year from gastric and hepatic problems. Worldwide peptic ulcers are 8.4% of the population. Stomach cancers, reflux disease, and helicobacter pylori infection are some of the causes. The acid peptic disease is caused by excessive amounts of acid produced. There are three phenotypes of gastroesophageal reflux disease which are mucosal injury which is reflux, related to endoscopic evidence, where the inner lining of the esophagus is abnormal, Barrett’s esophagus, and where there is no esophageal mucosal injury on the endoscopy is nonerosive reflux disease. Heartburn and regurgitation, pain in the abdominal area, and disturbance in sleep pattern are signs of typical reflux syndrome. Endoscopy-negative reflux disease and non-erosive reflux disease are based entirely on endoscopy. While the brain and gut are communicating continuously, a few like the hypothalamic-pituitary-adrenal axis are known to be associated with the modulation of the gut-brain axis. Drugs like antacids, omeprazole, rebamipide, revaprazan, and many new drugs are being studied. Policymakers have to keep this in mind as this condition is only increasing in the coming years with newer technology like artificial intelligence and a prophylactic vaccine could be the best or better alternative. Let us hope for better treatment options both non-invasive and invasive in the coming years with helicobacter infection being the main contender and with newer technology like artificial intelligence, let’s hope for better and improved drugs with negligible or very fewer adverse effects.

arrow_upward arrow_upward